Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Veralipride. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Veralipride. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Veralipride. |
| Hydrocodone | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Veralipride. |
| Magnesium sulfate | The therapeutic efficacy of Veralipride can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Veralipride may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Veralipride. |
| Mirtazapine | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Veralipride. |
| Orphenadrine | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Veralipride. |
| Pramipexole | Veralipride may increase the sedative activities of Pramipexole. |
| Ropinirole | Veralipride may increase the sedative activities of Ropinirole. |
| Rotigotine | Veralipride may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Veralipride. |
| Sodium oxybate | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Veralipride. |
| Thalidomide | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Veralipride may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Veralipride is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Veralipride is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Veralipride. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Veralipride. |
| Sulpiride | Veralipride may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Veralipride. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Veralipride. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Veralipride. |
| Mequitazine | Veralipride may increase the arrhythmogenic activities of Mequitazine. |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Veralipride is combined with Tetrabenazine. |
| Deutetrabenazine | The risk or severity of adverse effects can be increased when Veralipride is combined with Deutetrabenazine. |
| Ethanol | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Veralipride may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Veralipride. |
| Zimelidine | The risk or severity of adverse effects can be increased when Veralipride is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Veralipride is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Veralipride is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Veralipride is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Veralipride is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Veralipride is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Veralipride is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Veralipride is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Veralipride is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Veralipride is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Veralipride is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Veralipride is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Veralipride is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Veralipride is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Veralipride. |
| Indalpine | The risk or severity of adverse effects can be increased when Veralipride is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Veralipride is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Veralipride is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Veralipride. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Veralipride. |
| Zopiclone | The risk or severity of adverse effects can be increased when Veralipride is combined with Zopiclone. |
| Eletriptan | The risk or severity of adverse effects can be increased when Eletriptan is combined with Veralipride. |
| Cabergoline | The risk or severity of adverse effects can be increased when Cabergoline is combined with Veralipride. |
| Zolmitriptan | The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Veralipride. |
| Dihydroergotamine | The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Veralipride. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Veralipride. |
| Dextromethorphan | The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Veralipride. |
| Mazindol | The risk or severity of adverse effects can be increased when Mazindol is combined with Veralipride. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Veralipride. |
| Sumatriptan | The risk or severity of adverse effects can be increased when Sumatriptan is combined with Veralipride. |
| Ergotamine | The risk or severity of adverse effects can be increased when Ergotamine is combined with Veralipride. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Veralipride. |
| Almotriptan | The risk or severity of adverse effects can be increased when Almotriptan is combined with Veralipride. |
| Naratriptan | The risk or severity of adverse effects can be increased when Naratriptan is combined with Veralipride. |
| Rizatriptan | The risk or severity of adverse effects can be increased when Rizatriptan is combined with Veralipride. |
| Frovatriptan | The risk or severity of adverse effects can be increased when Frovatriptan is combined with Veralipride. |
| Ergoloid mesylate | The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Veralipride. |
| Chlorpheniramine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Veralipride. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Veralipride. |
| Bromocriptine | The risk or severity of adverse effects can be increased when Bromocriptine is combined with Veralipride. |
| Ergometrine | The risk or severity of adverse effects can be increased when Ergometrine is combined with Veralipride. |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Veralipride. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Veralipride. |
| Etoperidone | The risk or severity of adverse effects can be increased when Etoperidone is combined with Veralipride. |
| Lorpiprazole | The risk or severity of adverse effects can be increased when Lorpiprazole is combined with Veralipride. |
| Amphetamine | Veralipride may decrease the stimulatory activities of Amphetamine. |
| Phentermine | Veralipride may decrease the stimulatory activities of Phentermine. |
| Pseudoephedrine | Veralipride may decrease the stimulatory activities of Pseudoephedrine. |
| Benzphetamine | Veralipride may decrease the stimulatory activities of Benzphetamine. |
| Diethylpropion | Veralipride may decrease the stimulatory activities of Diethylpropion. |
| Lisdexamfetamine | Veralipride may decrease the stimulatory activities of Lisdexamfetamine. |
| Mephentermine | Veralipride may decrease the stimulatory activities of Mephentermine. |
| MMDA | Veralipride may decrease the stimulatory activities of MMDA. |
| 2,5-Dimethoxy-4-ethylamphetamine | Veralipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. |
| Chlorphentermine | Veralipride may decrease the stimulatory activities of Chlorphentermine. |
| Methylenedioxyethamphetamine | Veralipride may decrease the stimulatory activities of Methylenedioxyethamphetamine. |
| Dextroamphetamine | Veralipride may decrease the stimulatory activities of Dextroamphetamine. |
| Metamfetamine | Veralipride may decrease the stimulatory activities of Metamfetamine. |
| Iofetamine I-123 | Veralipride may decrease the stimulatory activities of Iofetamine I-123. |
| Ritobegron | Veralipride may decrease the stimulatory activities of Ritobegron. |
| Mephedrone | Veralipride may decrease the stimulatory activities of Mephedrone. |